Literature DB >> 3154305

Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure.

K Chatterjee1, L H Opie.   

Abstract

ACE inhibitors have emerged as important pharmacologic agents for treatment of hypertension and heart failure. Attenuation or inhibition of angiotensin mediated vasoconstriction appears to be the principal mechanism for the reduction of arterial pressure and systemic vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3154305     DOI: 10.1007/bf02125827

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  27 in total

Review 1.  Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

2.  Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.

Authors:  M A Creager; J L Halperin; D B Bernard; D P Faxon; C D Melidossian; H Gavras; T J Ryan
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

3.  Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.

Authors:  T B Levine; J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

4.  Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study.

Authors:  J L Rouleau; K Chatterjee; W Benge; W W Parmley; B Hiramatsu
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

5.  Ulceration of the tongue: a complication of captopril therapy.

Authors:  M G Nicholls; A H Maslowski; H Ikram; E A Espiner
Journal:  Ann Intern Med       Date:  1981-05       Impact factor: 25.391

6.  Long-term treatment of congestive heart failure by captopril: hemodynamic, biological and clinical effects.

Authors:  J G Kayanakis; J M Fauvel; P Giraud; J P Bounhoure
Journal:  Eur Heart J       Date:  1981-02       Impact factor: 29.983

7.  Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.

Authors:  R D Magorien; D W Triffon; C E Desch; W H Bay; D V Unverferth; C V Leier
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

8.  Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia.

Authors:  V J Dzau; N K Hollenberg
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

9.  Angiotensin converting enzyme inhibition in patients with congestive heart failure.

Authors:  H Gavras; D P Faxon; J Berkoben; H R Brunner; T J Ryan
Journal:  Circulation       Date:  1978-11       Impact factor: 29.690

Review 10.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

View more
  3 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Cardiorespiratory effects of continuous i.v. administration of the ACE inhibitor enalaprilat in the critically ill.

Authors:  J Boldt; M Müller; M Heesen; K Härter; G Hempelmann
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 3.  ACE inhibitors for the treatment of myocardial ischemia?

Authors:  C Linder; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.